A PHASE 1, NON-RANDOMIZED, OPEN-LABEL, SINGLE-DOSE STUDY TO EVALUATE THE PHARMACOKINETICS, SAFETY AND TOLERABILITY OF PF-04965842 IN SUBJECTS WITH RENAL IMPAIRMENT AND IN HEALTHY SUBJECTS WITH NORMAL RENAL FUNCTION
Phase of Trial: Phase I
Latest Information Update: 26 Nov 2019
Price : $35 *
At a glance
- Drugs Abrocitinib (Primary)
- Indications Atopic dermatitis
- Focus Pharmacokinetics
- Sponsors Pfizer
- 21 Nov 2019 Status changed from recruiting to completed.
- 11 Nov 2019 Planned End Date changed from 21 Jan 2020 to 5 Nov 2019.
- 30 Sep 2019 Planned primary completion date changed from 1 Jan 2020 to 21 Jan 2020.